NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Abroad (travel likely)RecruitingPHASE2

Conditions

Nanoliposomal Irinotecan · Cadonilimab · Oxaliplatin · Capecitabine · First-Line · Advanced Cancer · Pancreatic Adenocarcinoma · Drug Use

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

Small Bowel Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Tampa, United States · Chicago, United States

Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

Esophageal Adenocarcinoma · Gastric Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Madison, United States

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Rhabdomyosarcoma

Abroad (travel likely)RecruitingPHASE2

Palo Alto, United States · Memphis, United States

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Abroad (travel likely)RecruitingPHASE2

Madison, United States